Using Value Assessment/Health Technology Assessment in Pursuing Innovation and Access in a Pandemic
This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve scientific credibility and relevance of VA/HTA to pandemic preparedness. Where have our usual VA/HTA approaches worked and where have they proven inadequate to the challenges presented by COVID-19? Based on our learnings throughout the series, what are the emerging needs for methods, scientific research, public health, and defining and building consensus? What are the most immediate priorities for supporting innovation and access at both US and international levels. Does value-based pricing apply in the pandemic context? How do we coordinate public and private investment in these interventions and treatments?
Define US and global future research needs (methods, data, etc.) to support effective VA/HTA related to COVID-19
Define important considerations to balance access, affordability, and incentives to innovate for diagnostics, treatments, and vaccines for COVID-19
Discuss current public health gaps and how to prioritize necessary investment with limited resources
Evaluate coordination of different stakeholders in the US, and cross-country collaboration
Original Air Date: Thursday, November 12, 2020 Length: 75 minutes
The Role of Public Health – How can VA/HTA inform pandemic policy interventions and public resource allocation?
COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?
Describe how to incorporate policy and non-pharmaceutical interventions in VA/HTA
Discuss how VA/HTA accounts for effect of new treatments on non-COVID related care and the long-run health and mutli-sectoral impacts
Consider how to address public health infrastructure investment, and how to set priorities
Define methods that can help evaluate and prioritize policy interventions
Articulate the role of US and global government agencies and other stakeholders in public health investment
Original Air Date: Friday, October 23, 2020 Length: 75 minutes
Balancing Economics and Ethics: How Can VA/HTA Support Equitable Resource Allocation?
Evolving data from COVID-19 tell the story we already know: the impact of this disease affects – especially people of color – disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as discerning how to apply such findings, how must we address questions of ethics and equity?
After attending this webinar, participants will be able to:
Discuss key ethical issues in allocating limited resources in fighting against COVID-19 in the US and globally
Consider how to account for vulnerable populations especially at risk, and their needs
Evaluate importance of equity in VA/HTA
Identify methods and their readiness to address equity in distribution of tests, treatments, and vaccines
Original Air Date: Monday, September 21, 2020
Length: 75 minutes
The methods, assumptions, and inputs in Value Assessment (VA) and Health Technology Assessment (HTA) are an evolving debate in the US, as we seek to balance questions of population health-driven resource allocation with the unique needs of health system, employer, payer, and societal decision-making and the emerging science of patient heterogeneity and precision medicine.
Original Air Date: Thursday, August 27, 2020 at 4:30 PM EDT
Length: 75 minutes
How Should The COVID-19 Pandemic Challenge Conventional Wisdom About VA/HTA?
During the COVID-19 pandemic, it is clear that our views on healthcare access, the role of scientific research, and the need for global collaboration in pursuing effective and cost-effective care has been affected. The first webinar in the joint ISPOR-IVI webinar series brings together international and US thought leaders to discuss ongoing key challenges faced by the healthcare industry in regard to health technology assessment and value assessment.
Original Air Date: Wednesday, July 29, 2020 at 12:30 PM EDT Length: 60 minutes
In this webinar, which is designed for all audiences, IVI’s team provides and overview of the model, how it generates customized data on different non-small cell lung cancer therapies and how these data-driven insights unlock value for healthcare stakeholders.
Original Air Date: February 25, 2019 at 3:00 PM EST
Length: 60 minutes
IVI’s team, led by Jeroen Jansen and Devin Incerti, present an overview to foster a deeper understanding of the entirety of the IVI-NSCLC model package. The presenters will walk you through the key components of the open-source model, how the IVI model generates customized information on EGFR+ NSCLC treatment sequences, and how to apply the information in assessing value in health care among different populations.
Original Air Date: February 27, 2019 at 2:30 PM EST Length: 90 minutes
Measuring the Value of Health Care Treatments: Time for a New Approach
While different health care stakeholders have different perceptions of value, traditional value assessments are often “black boxes” that only account for a single perspective or a single population. For that reason, existing value frameworks tend to fall short for many individual stakeholders. The Open-Source Value Project seeks to change that by creating flexible, transparent, iterative, and consensus-based modeling platforms for specific diseases.
IVI has recently released its model of value assessment for rheumatoid arthritis (RA). Join IVI for a webinar to better understand how the OSVP process works, learn about our first model in RA, and find out how you can get involved.
Original Air Date: December 12, 2017 at 4:00 PM EST Length: 59 minutes
Creating Open-Source Models for Value Assessment: A Detailed Discussion of the IVI Rheumatoid Arthritis Model
Open-Source Value Project (OSVP) models are built to be entirely open-source, allowing anyone to customize the tool depending on their own assumptions and understanding of value. IVI has released the source code, documentation and suite of tools for its open-source model of value assessment for rheumatoid arthritis (RA) into the public domain. Our R package and highly customizable model interfaces allow experienced users to choose from over 300 different model structures, vary nearly all model inputs, and assess value using either cost-effectiveness or multi-criteria decision analytic approaches.
Are you interested in the technical and methodological aspects of the model? Join IVI for a webinar about the IVI-RA model and IVI’s open-source modeling approach. Presenters will walk you through the key components of the open-source consensus-based model, how the IVI model generates customized information on rheumatoid arthritis treatments, and how to apply the information in assessing value in health care.
Original Air Date: December 14, 2017 at 4:00 PM EST Length: 59 minutes